vs
NEUROCRINE BIOSCIENCES INC（NBIX）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是RBC Bearings INC的1.7倍（$805.5M vs $461.6M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs 14.6%，领先4.5%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 17.0%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $99.1M），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 5.6%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
NBIX vs RBC — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $461.6M |
| 净利润 | $153.7M | $67.4M |
| 毛利率 | 97.8% | 44.3% |
| 营业利润率 | 26.2% | 22.3% |
| 净利率 | 19.1% | 14.6% |
| 营收同比 | 28.3% | 17.0% |
| 净利润同比 | 49.1% | 16.4% |
| 每股收益（稀释后） | $1.49 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $805.5M | $461.6M | ||
| Q3 25 | $794.9M | $455.3M | ||
| Q2 25 | $687.5M | $436.0M | ||
| Q1 25 | $572.6M | $437.7M | ||
| Q4 24 | $627.7M | $394.4M | ||
| Q3 24 | $622.1M | $397.9M | ||
| Q2 24 | $590.2M | $406.3M | ||
| Q1 24 | $515.3M | $413.7M |
| Q4 25 | $153.7M | $67.4M | ||
| Q3 25 | $209.5M | $60.0M | ||
| Q2 25 | $107.5M | $68.5M | ||
| Q1 25 | $7.9M | $72.7M | ||
| Q4 24 | $103.1M | $57.9M | ||
| Q3 24 | $129.8M | $54.2M | ||
| Q2 24 | $65.0M | $61.4M | ||
| Q1 24 | $43.4M | — |
| Q4 25 | 97.8% | 44.3% | ||
| Q3 25 | 98.2% | 44.1% | ||
| Q2 25 | 98.4% | 44.8% | ||
| Q1 25 | 98.4% | 44.2% | ||
| Q4 24 | 98.5% | 44.3% | ||
| Q3 24 | 98.7% | 43.7% | ||
| Q2 24 | 98.4% | 45.3% | ||
| Q1 24 | 98.5% | 43.1% |
| Q4 25 | 26.2% | 22.3% | ||
| Q3 25 | 30.1% | 21.5% | ||
| Q2 25 | 21.2% | 23.2% | ||
| Q1 25 | 4.1% | 23.0% | ||
| Q4 24 | 22.6% | 21.7% | ||
| Q3 24 | 29.5% | 21.6% | ||
| Q2 24 | 24.6% | 24.0% | ||
| Q1 24 | 19.3% | 22.8% |
| Q4 25 | 19.1% | 14.6% | ||
| Q3 25 | 26.4% | 13.2% | ||
| Q2 25 | 15.6% | 15.7% | ||
| Q1 25 | 1.4% | 16.6% | ||
| Q4 24 | 16.4% | 14.7% | ||
| Q3 24 | 20.9% | 13.6% | ||
| Q2 24 | 11.0% | 15.1% | ||
| Q1 24 | 8.4% | — |
| Q4 25 | $1.49 | $2.13 | ||
| Q3 25 | $2.04 | $1.90 | ||
| Q2 25 | $1.06 | $2.17 | ||
| Q1 25 | $0.08 | $2.33 | ||
| Q4 24 | $1.00 | $1.82 | ||
| Q3 24 | $1.24 | $1.65 | ||
| Q2 24 | $0.63 | $1.90 | ||
| Q1 24 | $0.42 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $3.3B | $3.3B |
| 总资产 | $4.6B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $713.0M | $107.6M | ||
| Q3 25 | $340.2M | $91.2M | ||
| Q2 25 | $264.0M | $132.9M | ||
| Q1 25 | $194.1M | $36.8M | ||
| Q4 24 | $233.0M | — | ||
| Q3 24 | $349.1M | — | ||
| Q2 24 | $139.7M | $76.8M | ||
| Q1 24 | $396.3M | $63.5M |
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $3.3B | $3.3B | ||
| Q3 25 | $3.0B | $3.2B | ||
| Q2 25 | $2.7B | $3.1B | ||
| Q1 25 | $2.5B | $3.0B | ||
| Q4 24 | $2.6B | $2.9B | ||
| Q3 24 | $2.7B | $2.9B | ||
| Q2 24 | $2.5B | $2.8B | ||
| Q1 24 | $2.4B | $2.8B |
| Q4 25 | $4.6B | $5.1B | ||
| Q3 25 | $4.3B | $5.1B | ||
| Q2 25 | $3.9B | $4.8B | ||
| Q1 25 | $3.7B | $4.7B | ||
| Q4 24 | $3.7B | $4.7B | ||
| Q3 24 | $3.5B | $4.7B | ||
| Q2 24 | $3.3B | $4.7B | ||
| Q1 24 | $3.5B | $4.7B |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $99.1M |
| 自由现金流率自由现金流/营收 | 47.9% | 21.5% |
| 资本支出强度资本支出/营收 | 0.3% | 5.0% |
| 现金转化率经营现金流/净利润 | 2.53× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $743.9M | — |
8季度趋势，按日历期对齐
| Q4 25 | $388.4M | $122.1M | ||
| Q3 25 | $227.5M | $88.4M | ||
| Q2 25 | $102.0M | $120.0M | ||
| Q1 25 | $64.8M | — | ||
| Q4 24 | $242.5M | $84.0M | ||
| Q3 24 | $158.0M | — | ||
| Q2 24 | $64.6M | $97.4M | ||
| Q1 24 | $130.3M | — |
| Q4 25 | $386.0M | $99.1M | ||
| Q3 25 | $214.3M | $71.7M | ||
| Q2 25 | $89.5M | $104.3M | ||
| Q1 25 | $54.1M | — | ||
| Q4 24 | $235.2M | $73.6M | ||
| Q3 24 | $149.9M | — | ||
| Q2 24 | $53.0M | $88.4M | ||
| Q1 24 | $119.1M | — |
| Q4 25 | 47.9% | 21.5% | ||
| Q3 25 | 27.0% | 15.7% | ||
| Q2 25 | 13.0% | 23.9% | ||
| Q1 25 | 9.4% | — | ||
| Q4 24 | 37.5% | 18.7% | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 9.0% | 21.8% | ||
| Q1 24 | 23.1% | — |
| Q4 25 | 0.3% | 5.0% | ||
| Q3 25 | 1.7% | 3.7% | ||
| Q2 25 | 1.8% | 3.6% | ||
| Q1 25 | 1.9% | 3.2% | ||
| Q4 24 | 1.2% | 2.6% | ||
| Q3 24 | 1.3% | 4.1% | ||
| Q2 24 | 2.0% | 2.2% | ||
| Q1 24 | 2.2% | — |
| Q4 25 | 2.53× | 1.81× | ||
| Q3 25 | 1.09× | 1.47× | ||
| Q2 25 | 0.95× | 1.75× | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | 1.45× | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | 1.59× | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
